Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
170.50    5.75 (3.49%)
Bid:
168.00
Ask:
172.00
Spread: 4.00 (2.381%)
Market Cap: £1.47b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Hutchmed News

Hutchmed celebrates cancer drug approval in hometown of Hong Kong
30 Jan 2024

Hutchmed celebrates cancer drug approval in hometown of Hong Kong

(Alliance News) - Hutchmed (China) Ltd on Tuesday touted progress in Hong Kong, after its oral therapy for metastatic colorectal cancer received marke...

Hutchmed application for thrombocytopenia treatment accepted in China
11 Jan 2024

Hutchmed application for thrombocytopenia treatment accepted in China

(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosi...

TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau
11 Jan 2024

TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau

(Alliance News) - Hutchmed Ltd on Thursday said that its novel treatment for haematological malignancies and immune diseases had been progressed to th...

IN BRIEF: Hutchmed China renews deals with "substantial" shareholders
21 Dec 2023

IN BRIEF: Hutchmed China renews deals with "substantial" shareholders

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Agrees with "substantial shareholder" Sinopharm...

Hutchmed completes enrolment for fruquintinib trial
13 Dec 2023

Hutchmed completes enrolment for fruquintinib trial

(Alliance News) - Hutchmed (China) Ltd on Wednesday said it has completed enrolment of its phase II/III trial of fruquintinib.

Hutchmed completes trial enrolment, keeps drugs on China funding list
13 Dec 2023

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs ...

Hutchmed completes trial enrolment, keeps drugs on China funding list
13 Dec 2023

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs ...

Hutchmed hails Takeda's fruquintinib approval from US for cancer form
9 Nov 2023

Hutchmed hails Takeda's fruquintinib approval from US for cancer form

(Alliance News) - Hutchmed (China) Ltd on Thursday announced that the Tokyo-based drug maker, Takeda Pharmaceutical Co Ltd, has received US approval o...